Tofogliflozin
Based on 4 publication(s) in Google Scholar
Tofogliflozin (CSG-452) is a highly efficient and selective inhibitor of SGLT2, with Ki values of 2.9, 14.9 and 6.4nM for human, rat and mouse SGLT2 respectively.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.38%
- CAS. Nr.: 903565-83-3
- Formel: C22H26O6
- Molecular Weight:386.44
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-10450
DapagliflozinSGLT2 Inhibitor -
HY-15409
EmpagliflozinSGLT2 Inhibitor -
HY-10451
CanagliflozinSGLT2 Inhibitor -
HY-N0142
PhloretinAnti-inflammatory Agent -
HY-15516
SotagliflozinSGLT Inhibitor -
HY-14894
IpragliflozinSGLT Inhibitor -
HY-15461
ErtugliflozinSGLT2 Inhibitor -
HY-15461A
Ertugliflozin L-pyroglutamic acidSGLT2 Inhibitor -
HY-10450R
Dapagliflozin (Standard)SGLT2 Inhibitor -
HY-I0383
Canagliflozin hemihydrateSGLT Inhibitor -
HY-15409R
Empagliflozin (Standard)SGLT2 Inhibitor -
HY-10450A
Dapagliflozin ((2S)-1,2-propanediol, hydrate)SGLT2 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Tofogliflozin
More
Biologische Aktivität
Beschreibung
IC50 & Target
|
SGLT2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
2.9 nM
Compound: 16d, CSG452, Tofogliflozin
|
Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
|
[PMID: 22889351] |
| CHO | IC50 |
8444 nM
Compound: 16d, CSG452, Tofogliflozin
|
Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins
|
[PMID: 22889351] |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 903565-83-3
-
Appearance Solid
-
Molecular Weight 386.44
-
Formel C22H26O6
-
Color White to off-white
-
SMILES
O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@]21OCC3=CC=C(CC4=CC=C(CC)C=C4)C=C23
-
Synonyms
CSG452; R-7201
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. [Abstract]2018 Jun:152:45-59. PMID: 29551587 -
-
J Chromatogr B Analyt Technol Biomed Life Sci
Simultaneous detection of 24 oral antidiabetic drugs and their metabolites in urine by liquid chromatography-tandem mass spectrometry. [Abstract]2020 Mar 15:1141:122020. PMID: 32062369 -
Reinheit & Dokumentation
-
Data Sheet (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Nagata T, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013 Oct;170(3):519-31. [Content Brief]
[2]. Yamane M, et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica. 2014 Oct 28:1-9. [Content Brief]
[3]. Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701. [Content Brief]
[4]. Nagata T, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Tofogliflozin Related Classifications
HY-14902 Related Classifications
Powered by Bioz